Naveris develops liquid biopsies that utilize proprietary technology to detect HPV-related cancers through highly sensitive blood tests, enabling earlier diagnosis than traditional imaging or biopsies. Their lead product, NavDx®, provides real-time monitoring of cancer recurrence, improving patient outcomes by facilitating timely interventions.
Funding
$85.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for detecting and monitoring HPV-related cancers, such as imaging and tissue biopsies, often detect the disease at later stages, potentially delaying treatment and impacting patient outcomes. These methods can also be invasive and may not provide real-time monitoring of cancer recurrence.
Solution
Naveris offers liquid biopsy technology designed for the early detection and monitoring of HPV-related cancers. Their primary product, NavDx®, utilizes a proprietary method to detect cancer through highly sensitive blood tests, allowing for earlier diagnosis compared to traditional methods. NavDx® provides real-time monitoring of cancer recurrence, enabling timely interventions and potentially improving patient outcomes. The non-invasive nature of the liquid biopsy offers a less burdensome approach to cancer surveillance.
Target Audience
The primary target audience includes oncologists and other healthcare professionals involved in the diagnosis, treatment, and monitoring of patients with HPV-related cancers.
Features
- Ultrasensitive detection of HPV-related cancers through blood-based liquid biopsies.
- Proprietary technology for early cancer detection, surpassing the sensitivity of traditional imaging and biopsies.
- Real-time monitoring of cancer recurrence to facilitate timely clinical interventions.
- Non-invasive procedure, reducing patient burden compared to traditional biopsies.